AstraZeneca's COVID Vaxzevria gets approval in EU as booster dose
Ibrahim Akcengiz/E+ via Getty Images


The European Medicine Agency granted approval to AstraZeneca's (NASDAQ:AZN) COVID-19 vaccine Vaxzevria for use as a third dose booster shot in adults in the EU.
The approval follows recommendation by the EMA's the Committee for Medicinal Products for Human Use (CHMP) to greenlight the vaccine booster last week.

The British pharma giant said that Vaxzevria can now be used as a third dose booster in people previously given a primary vaccine schedule of either Vaxzevria or an EU-approved mRNA COVID vaccine.
AstraZeneca (AZN) noted that Vaxzevria is already authorized as a booster for people who had previously received Vaxevria as primary vaccine in the U.K., and certain countries in Asia and Latin America.
Vaxzevria generated ~$1.15B in revenue in Q1 for the company.